Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Acorda Therapeutics, Inc. (ACOR)
|
Add to portfolio |
|
|
|
| Price: |
$2.50
| | Metrics |
| OS: |
1.24
|
M
| |
|
|
| Market cap: |
$3.11
|
M
| |
-265
|
% ROIC
|
|
Net debt:
|
$151
|
M
| |
|
|
|
EV:
|
$154
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($62.3)
|
M
| |
|
|
| EPS |
($8.24)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 129.1 | 153.0 | 192.4 | 471.4 | 588.3 | 519.6 | 492.7 | 401.5 |
| Revenue growth | -15.6% | -20.5% | -59.2% | -19.9% | 13.2% | 5.5% | 22.7% | 19.3% |
| Cost of goods sold | 40.8 | 33.5 | 34.8 | 97.6 | 111.3 | 107.5 | 92.3 | 80.0 |
| Gross profit | 88.3 | 119.5 | 157.6 | 373.8 | 477.0 | 412.1 | 400.4 | 321.5 |
| Gross margin | 68.4% | 78.1% | 81.9% | 79.3% | 81.1% | 79.3% | 81.3% | 80.1% |
| Selling, general and administrative | 124.4 | 152.6 | 192.8 | 172.3 | 181.6 | 235.4 | 205.6 | 201.8 |
| Research and development | 10.4 | 23.0 | 60.1 | 106.4 | 166.1 | 203.4 | 149.2 | 73.5 |
| EBITA | -42.5 | -47.1 | -182.3 | 150.2 | 128.6 | -27.4 | 44.9 | 43.4 |
| EBITA margin | -32.9% | -30.8% | -94.7% | 31.9% | 21.9% | -5.3% | 9.1% | 10.8% |
| Amortization of intangibles | 30.8 | 30.8 | 25.6 | 1.7 | 23.8 | | | |
| EBIT | -73.2 | -77.8 | -207.9 | 148.5 | 104.8 | -27.4 | 44.9 | 43.4 |
| EBIT margin | -56.8% | -50.9% | -108.1% | 31.5% | 17.8% | -5.3% | 9.1% | 10.8% |
| Pre-tax income | -109.1 | -107.7 | -274.2 | 20.4 | -251.9 | -42.3 | 19.4 | 28.0 |
| Income taxes | -5.1 | -8.1 | -1.3 | -13.3 | -28.5 | -6.7 | 8.3 | 10.3 |
| Tax rate | 4.7% | 7.5% | 0.5% | | 11.3% | 15.8% | 42.9% | 36.9% |
| Net income | -104.0 | -99.6 | -273.0 | 33.7 | -223.4 | -34.6 | 11.1 | 17.7 |
| Net margin | -80.5% | -65.1% | -141.9% | 7.1% | -38.0% | -6.7% | 2.2% | 4.4% |
| |
| Diluted EPS | ($9.79) | ($12.32) | ($34.43) | $0.71 | ($4.86) | ($0.76) | $0.25 | $0.42 |
| Shares outstanding (diluted) | 10.6 | 8.1 | 7.9 | 47.3 | 46.0 | 45.3 | 43.6 | 42.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|